149977-36-6

Basic information

• Product Name: Thiophene, 3-(2-nitro-1-propenyl)-
• Synonyms: 3-(2-NITROPROP-1-ENYL)THIOPHENE;(E)-3-(2-nitroprop-1-en-1-yl)thiophene
• CAS NO: 149977-36-6
• Molecular Formula: C₇H₇NO₂S
• Molecular Weight: 169.2
• Mol File: 149977-36-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Thiophene, 3-(2-nitro-1-propenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiophene, 3-(2-nitro-1-propenyl)-(149977-36-6)
• EPA Substance Registry System: Thiophene, 3-(2-nitro-1-propenyl)-(149977-36-6)

Safety Data

• Hazardous Substances Data: 149977-36-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Thiophene, 3-(2-nitro-1-propenyl)is used as a building block for the synthesis of various pharmaceuticals. Its unique chemical and physical properties make it suitable for the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
Thiophene, 3-(2-nitro-1-propenyl)is used in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and unique properties contribute to the development of effective and environmentally friendly agricultural products.
Used in Dye Industry:
Thiophene, 3-(2-nitro-1-propenyl)is used in the production of dyes, due to its ability to impart color and stability to various materials. Its unique properties make it a valuable component in the creation of high-quality dyes for different applications.
Used in Advanced Materials Production:
Thiophene, 3-(2-nitro-1-propenyl)is used as a building block in the production of advanced materials, such as polymers and composites. Its unique chemical and physical properties contribute to the development of innovative materials with improved performance and functionality.
Used in Specialty Chemicals Industry:
Thiophene, 3-(2-nitro-1-propenyl)is used in the synthesis of various specialty chemicals, including those used in chemical reactions and industrial processes. Its reactivity and unique properties make it a valuable component in the development of new and improved specialty chemicals.

Upstream product

• 498-62-4 3-thiophene carboxaldehyde 
• 79-24-3 Nitroethane 

Downstream Products

• 1997387-43-5 C₁₉H₂₇N₃O₂S 
• 86188-25-2 (RS)-1-(thiophen-3-yl)propan-2-amine hydrochloride 
• 1997387-43-5 1-[(R)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-((S)-1-(thiophen-3-yl)propan-2-yl)urea 
• 1997387-43-5 1-[(R)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-((R)-1-(thiophen-3-yl)propan-2-yl)urea 
• 1997387-43-5 1-[(S)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-((R)-1-(thiophen-3-yl)propan-2-yl)urea 
• 1997387-43-5 1-[(2S)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-3-[(2S)-1-(thiophen-3-yl)propan-2-yl]urea 
• 857521-94-9 methyl-(1-methyl-2-[3]thienyl-ethyl)-amine 
• 149977-81-1 3-(2-amino-1-propyl)thiophene 
• 62119-77-1 1-(thiophen-3-yl)propan-2-one 

Relevant articles and documents

Guanidine-containing compound as well as preparation method and application thereof

The invention discloses a cyanoguanidine-containing compound as well as a preparation method and application thereof. The invention also discloses a composition containing the cyanoguanidine-structured compound (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention also discloses application thereof in preparation of analgesic drugs. The compounds of the invention are useful in the treatment of various pain.

Biased agonist and medical application thereof

The invention relates to compounds shown in structural formulas I and II, stereoisomers or pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the compounds, the stereoisomers or the pharmaceutically acceptable salts thereof as active ingredients, and uses of the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof in preparation ofanalgesic drugs.

Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors

The nuclear protein poly(ADP-ribose) polymerases-1/2 (PARP-1/2) are involved in DNA repair damaged by endogenous or exogenous process. And PARP-1/2 inhibitors have been proved to be clinically efficacious for DNA repair deficient tumors in the past decade

Synthesis, antiproliferative and pro-apoptotic effects of nitrostyrenes and related compounds in Burkitt’s lymphoma

Background: Cancers of the lymphatic cells (lymphomas) account for approximately 12% of malignant diseases worldwide. The nitrostyrene scaffold is identified as a lead target structure for the development of particularly effective compounds targeting Burkitt’s lymphoma (BL). Objectives: The aims of the curent study were to synthesise a panel of nitrostyrene compounds and to evaluate their activity in Burkitt’s lymphoma (BL). Methods: A panel of structurally varied compounds were designed and synthesised using Henry Knoevenagel condensation reactions. Single crystal X-Ray analysis confirmed the E configuration for six examples of these novel structures. A number of nitrostyrene-related compounds were also investigated including 1,3-bis(aryl)-2-nitropropenes together with heterocyclic scaffolds containing the nitrovinyl pharmacophore such as 3-nitro-2-phenyl-2H-chromenes. The antiproliferative activities of the compounds were evaluated using the BL cell lines EBV- MUTU-1 and EBV+ DG-75 (chemoresistant) to establish preliminary structure-activity relationships. Results: Lead compounds with optimized nitrostyrene scaffolds and 3-nitro-2-phenyl-2Hchromene structures were successfully established with typical IC50 values of 0.45 μM and 0.47 μM in MUTU-1 cells and 1.41 μM and 1.92 μM, respectively, in DG-75 cells. The mechanism of cell death was identified as apoptotic and the lead compound was found to elicit comparable apoptotic effects to Taxol in Burkitt’s lymphoma cell lines MUTU-1 and DG-75. Conclusion: This class of pharmaceutically active compounds with potential for the treatment of Burkitt’s lymphoma suggest a potential role for nitrostyrene based agents in chemotherapy.

MU OPIOID RECEPTOR MODULATORS

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

MU OPIOID RECEPTOR MODULATORS

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Palladium-Catalyzed Intramolecular Cyclization of Nitroalkenes: Synthesis of Thienopyrroles

In the presence of carbon monoxide, the palladium/phenanthroline system catalyzes the intramolecular amination of thiophene rings following the reduction of a nitroalkene moiety directly attached to the S-heterocyclic ring. Optimization of the ligand and reaction conditions allowed the synthesis of a series of thienopyrroles aryl/alkyl-substituted at either the 2- or 3-position of the pyrrole ring. By using low pressures of carbon monoxide (5 bars), high yields of fused bicyclic compounds have been obtained (up to 98 % yield).

Design of phosphorus ligands with deep chiral pockets: Practical Synthesis of chiral β-arylamines by asymmetric hydrogenation

WingPhos, a C2-symmetric bisphosphorus ligand with a deep and well-defined chiral pocket was developed. It has shown high efficiency in the rhodium-catalyzed asymmetric hydrogenation of (E)-β-aryl-N-acetyl enamides, cyclic β-aryl enamides, and heterocyclic β-aryl enamides. A series of chiral β-arylisopropylamines, 2-aminotetralines, and 3-aminochromans can be synthesized with excellent ee values (nbd=3,5-norbornadiene; TON=turnover number). Copyright

Heteroarylisopropylamines as MAO inhibitors

The in vitro monoamine oxidase inhibitory (MAOI) activities of 11 heteroarylisopropylamines vis-a-vis MAO-A and MAO-B were described and interpreted in terms of possible interactions with the enzyme active site. Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin.

Thieno tetrahydropyridines useful as class III antiarrhythmic agents

This invention relates to thieno tetrahydropyridine and isoquinoline derivative compounds which are useful as antiarrhythmic agents, pharmaceutical compositions comprising such compounds, novel intermediates for their preparation and their methods of use. More particularly these thieno tetrahydropyridine and isoquinoline derivative compounds have been demonstrated to increase the effective refractory period (ERP) of isolated perfused cardiac tissue in vitro.